Abstract
Tower Microneedle was developed with minimal ocular tissue damages even reflux, while no study was reported with intravitreal injection of ophthalmic drug via Tower Microneedle into the eye. Intravitreal injection of anti-vascular endothelial growth factor antibodies via the Tower Microneedle or a 30-G hypodermic needle was performed 1 week after argon laser irradiation into the retina of the mouse models. Less bleb formation was occurred with Tower Microneedle than 30-G hypodermic needle, while both needles led to comparable degrees of anti-angiogenesis in the retina after intravitreal injection of anti-vascular endothelial growth factor antibodies over 100 ng/μL concentration. Conclusively, the Tower Microneedle can deliver anti-vascular endothelial growth factor antibody into the posterior segment of the eye with minimal bleb formation after intravitreal injection.
| Original language | English |
|---|---|
| Pages (from-to) | 232-238 |
| Number of pages | 7 |
| Journal | Biochip Journal |
| Volume | 9 |
| Issue number | 3 |
| DOIs | |
| Publication status | Published - 2015 Sep 28 |
Fingerprint
All Science Journal Classification (ASJC) codes
- Biotechnology
- Bioengineering
- Biomedical Engineering
- Electrical and Electronic Engineering
Cite this
}
Intravitreal injection of anti-vascular endothelial growth factor (anti-VEGF) antibody via Tower Microneedle. / Lee, Chang Yeol; Ma, Yonghao; You, Yong Sung; Kim, Hyoung Eun; Byeon, Young Dook; Jung, Hyungil.
In: Biochip Journal, Vol. 9, No. 3, 28.09.2015, p. 232-238.Research output: Contribution to journal › Article
TY - JOUR
T1 - Intravitreal injection of anti-vascular endothelial growth factor (anti-VEGF) antibody via Tower Microneedle
AU - Lee, Chang Yeol
AU - Ma, Yonghao
AU - You, Yong Sung
AU - Kim, Hyoung Eun
AU - Byeon, Young Dook
AU - Jung, Hyungil
PY - 2015/9/28
Y1 - 2015/9/28
N2 - Tower Microneedle was developed with minimal ocular tissue damages even reflux, while no study was reported with intravitreal injection of ophthalmic drug via Tower Microneedle into the eye. Intravitreal injection of anti-vascular endothelial growth factor antibodies via the Tower Microneedle or a 30-G hypodermic needle was performed 1 week after argon laser irradiation into the retina of the mouse models. Less bleb formation was occurred with Tower Microneedle than 30-G hypodermic needle, while both needles led to comparable degrees of anti-angiogenesis in the retina after intravitreal injection of anti-vascular endothelial growth factor antibodies over 100 ng/μL concentration. Conclusively, the Tower Microneedle can deliver anti-vascular endothelial growth factor antibody into the posterior segment of the eye with minimal bleb formation after intravitreal injection.
AB - Tower Microneedle was developed with minimal ocular tissue damages even reflux, while no study was reported with intravitreal injection of ophthalmic drug via Tower Microneedle into the eye. Intravitreal injection of anti-vascular endothelial growth factor antibodies via the Tower Microneedle or a 30-G hypodermic needle was performed 1 week after argon laser irradiation into the retina of the mouse models. Less bleb formation was occurred with Tower Microneedle than 30-G hypodermic needle, while both needles led to comparable degrees of anti-angiogenesis in the retina after intravitreal injection of anti-vascular endothelial growth factor antibodies over 100 ng/μL concentration. Conclusively, the Tower Microneedle can deliver anti-vascular endothelial growth factor antibody into the posterior segment of the eye with minimal bleb formation after intravitreal injection.
UR - http://www.scopus.com/inward/record.url?scp=84942304308&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84942304308&partnerID=8YFLogxK
U2 - 10.1007/s13206-015-9305-9
DO - 10.1007/s13206-015-9305-9
M3 - Article
VL - 9
SP - 232
EP - 238
JO - Biochip Journal
JF - Biochip Journal
SN - 1976-0280
IS - 3
ER -